Aerosol medication delivery apparatus and system

Surgery – Liquid medicament atomizer or sprayer – Pre-pressurized container holding medicament

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C128S200180

Reexamination Certificate

active

06293279

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to a portable aerosol medication delivery apparatus and system for administering a desired respirable dosage of a medication in aerosol form to a patient's lungs by oral inhalation.
BACKGROUND OF THE INVENTION
The use of aerosol medication delivery systems to administer medication in aerosol form to a patient's lungs by inhalation is well known in the art.
Conventional aerosol medication delivery systems include pressurized metered-dose inhalers (pMDIs). Conventional pMDIs typically have two components: a canister component in which the medication particles are stored under pressure in a suspension or solution form and a receptacle component used to hold and actuate the canister. The canister component typically includes a valved outlet from which the contents of the canister can be discharged. Aerosol medication is dispensed from the pMDI by applying a force on the canister component to push it into the receptacle component thereby opening the valved outlet and causing the medication particles to be conveyed from the valved outlet through the receptacle component and discharged from an outlet of the receptacle component. Upon discharge from the canister, the medication particles are “atomized” forming an aerosol. It is intended that the patient coordinate the discharge of aerosolized medication with his or her inhalation so that the medication particles are entrained in the patient's inspiratory flow and conveyed to the lungs. Typically, pMDIs have used propellants, such as chlorofluorocarbons (CFCs), to pressurize the contents of the canister and to propel the medication particles out of the outlet of the receptacle component.
Although conventional pMDIs have been widely used to provide many patients with the benefits of aerosol medication, conventional pMDIs have certain drawbacks. For example, an objective of aerosol therapy has been the optimization of the mass percentage of the respirable dose of an aerosol medication in order to optimize deposition in a patient's lungs to achieve a full therapeutic effect with the least possible side-effects. Conventional pMDIs may not have always been able to meet this objective.
One drawback associated with conventional pMDIs relates to the discharge velocity of the aerosol particles. Medication particles are stored under considerable pressure in the pMDI canister and as a consequence, their velocity may be high upon discharge.
Among other things, the effect of high velocity contributes to a significant number of aerosol medication particles impacting and depositing in the patient's oropharynx and upper airway rather than continuing their pathway through the upper airway and into the lungs. Such impaction and deposition may result in a significant portion of the medication dose being systemically absorbed or ingested. As documented in the literature [J. L. Rau, “Respiratory Care Pharmacology”, 4
th
ed. (1994, Mosby) at pp. 256-261; K. Meeran, A. Hattersley, J. Burrin, R. Shiner, K. Ibbertson K., “Oral and Inhaled Corticosteroids Reduce Bone Formation as Shown by Plasma Osteocalcin Levels”,
Am. J. Respir. Crit. Care Med
151:333-336], systemic absorption or ingestion of aerosol medication may cause a patient adverse side-effects, particularly when the aerosol medication is a corticosteroid. Some of these adverse side-effects include pharyngeal candidiasis, hoarseness, and adrenal suppression.
The high velocity of the aerosol medication particles may also accentuate the difficulty of a significant number of patients, particularly the very young and elderly, to coordinate actuation of the pMDI with inhalation of the aerosol medication particles generated. Failure to coordinate the actuation and inhalation maneuvers and failure to inhale slowly, have been documented by the literature [S. P. Newman, “Aerosol Deposition Considerations in Inhalation Therapy” Chest/88/2/August, 1985/Supplement] as contributing to a significant reduction in the number of aerosol medication particles inspired and deposited in a patient's lungs.
Impaction and deposition of aerosol medication particles on a patient's oropharynx and upper airway may also contribute to an unpleasant taste in a patient's mouth, particularly with certain medication solution or suspension formulations such as flunisolide.
In addition to high particle velocity, a significant number of large non-respirable medication particles may be produced upon discharge as a result of the medication suspension or solution formulation as well as the atomization process. As mentioned above, conventional pMDIs have used CFCs to propel the medication out of the pMDI actuator outlet. In view of environmental concerns with CFCs, there has been a growing interest in using non-CFC propellants, such as hydrofluoroalkanes (HFAs).
An inhalation valve is often used in conjunction with an aerosol medication delivery apparatus to deliver a medication in an aerosol form to a user's respiratory tract. Typically, an inhalation valve is disposed at the output end of an aerosolization chamber and prevents aerosolized medication from leaving the chamber when the inhalation valve is in a closed position. When a patient inhales, the inhalation valve opens and allows the aerosolized medication to enter the patient's respiratory tract. The inhalation valve is usually designed to close upon exhalation by the patient.
Prior art inhalation valves generally consist of a valve member and a valve seat. In some types of prior art valves, the outer perimeter of the valve member seals against the valve seat. In operation, the act of inhalation causes the outer perimeter of the valve to move away from the valve seat and allow aerosolized medication to flow through to the patient.
In another type of prior art inhalation valve, the valve member includes one or more slits that define flaps on the valve member. Typically, the valve seat has a plurality of openings defined by what is known as a spider-like framework. In operation, when the patient inhales the flaps move away from the spider-like framework to allow aerosolized medication to pass through the openings to the patient. Upon exhalation, the flaps move against the framework to cover the openings. A number of advantageous improvements and modifications can be made to these prior designs.
It is another object to provide a device which reduces the need for a patient to coordinate activation of a pMDI canister with inhalation.
It is a further object to provide a device that reduces the delivery of nonrespirable medication particles from a pMDI canister to a patient.
It is yet another object to provide a device that reduces the impaction of medication particles on a patient's oropharynx and upper airway.
It is still another object to provide a device for the delivery of aerosol medication from a pMDI canister that uses an HFA propellant instead of a CFC propellant.
SUMMARY OF THE INVENTION
In order to address the above noted objectives, as well as other objectives, the present invention provides an improved aerosol medication delivery apparatus. The aerosol medication delivery apparatus includes a canister-holding portion and a chamber housing. The canister-holding portion has a receptacle for receipt of a pMDI canister containing a medication and a propellant. The canister-holding portion has a discharge orifice communicating with the receptacle to direct an aerosol into an interior of the chamber housing at an input end thereof. The chamber housing also has an output end from which medication can be withdrawn by inhalation by a patient. The canister-holding portion and the chamber housing are coupled together by a mechanism that provides for the canister-holding portion to be retracted into the chamber housing for storage. The coupling mechanism also allows the canister-holding portion to be extracted from its storage position in the chamber housing and pivoted into position for use when dispensing medication. According to one aspect of the present invention,

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Aerosol medication delivery apparatus and system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aerosol medication delivery apparatus and system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aerosol medication delivery apparatus and system will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2472687

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.